An intensive, structured, mobile devices-based healthcare intervention to optimize the lipid-lowering therapy improves lipid control after an acute coronary syndrome
Ruiz Bustillo, Sonia (Institut Hospital del Mar d'Investigacions Mèdiques)
Badosa, Neus (Institut Hospital del Mar d'Investigacions Mèdiques)
Cabrera-Aguilera, Ignacio (Institut Hospital del Mar d'Investigacions Mèdiques)
Ivern, Consol (Institut Hospital del Mar d'Investigacions Mèdiques)
Llagostera-Martín, Marc (Hospital del Mar (Barcelona, Catalunya))
Mojón, Diana (Hospital del Mar (Barcelona, Catalunya))
Vicente, Miren (Hospital del Mar (Barcelona, Catalunya))
Ribas, Núria (Institut Hospital del Mar d'Investigacions Mèdiques)
Recasens, Lluis (Institut Hospital del Mar d'Investigacions Mèdiques)
Martí-Almor, Julio (Institut Hospital del Mar d'Investigacions Mèdiques)
Cladellas Capdevila, Mercè (Institut Hospital del Mar d'Investigacions Mèdiques)
Farré, Núria (Institut Hospital del Mar d'Investigacions Mèdiques)
Universitat Autònoma de Barcelona

Fecha:	2022
Resumen:	Despite the evidence, lipid-lowering treatment (LLT) in secondary prevention remains insufficient, and a low percentage of patients achieve the recommended LDL cholesterol (LDLc) levels by the guidelines. We aimed to evaluate the efficacy of an intensive, mobile devices-based healthcare lipid-lowering intervention after hospital discharge in patients hospitalized for acute coronary syndrome (ACS). Ambiespective register in which a mobile devices-based healthcare intervention including periodic follow-up, serial lipid level controls, and optimization of lipid-lowering therapy, if appropriate, was assessed in terms of serum lipid-level control at 12 weeks after discharge. A total of 497 patients, of which 462 (93%) correctly adhered to the optimization protocol, were included in the analysis. At the end of the optimization period, 327 (70. 7%) patients had LDLc levels ≤ 70 mg/dL. 40% of patients in the LDLc ≤ 70 mg/dL group were upgraded to very-high intensity lipid-lowering ability therapy vs. 60. 7% in the LDLc > 70 mg/dL group, p < 0. 001. Overall, 38. 5% of patients had at least a change in their LLT. Side effects were relatively infrequent (10. 7%). At 1-year follow-up, LDLc levels were measured by the primary care physician in 342 (68. 8%) of the whole cohort of 497 patients. In this group, 71. 1% of patients had LDLc levels ≤ 70 mg/dL. An intensive, structured, mobile devices-based healthcare intervention after an ACS is associated with more than 70% of patients reaching the LDLc levels recommended by the clinical guidelines. In patients with LDLc measured at 1-year follow-up, 71. 1% had LDLc levels ≤ 70 mg/dL.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Cardiovascular risk factors ; Ischemic heart disease ; Lipid-lowering therapy ; Mobile devices-based healthcare ; Secondary prevention
Publicado en:	Frontiers in Cardiovascular Medicine, Vol. 9 (july 2022) , ISSN 2297-055X

DOI: 10.3389/fcvm.2022.916031
PMID: 35958430

8 p, 297.4 KB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados